The mission of the Office of HIV Prevention and Care, in collaboration with community partners, is to reduce the incidence of HIV infections, to increase life expectancy for those infected, and to improve the quality of life for persons living with or affected by HIV. The charge of the office is to:
- Monitor the epidemic
- Improve public understanding of HIV
- Prevent or reduce behaviors that transmit HIV
- Increase individual knowledge of HIV serostatus
- Strengthen systems for referral to appropriate prevention and treatment services
Guidance for COVID-19 and Persons with HIV
Persons with HIV Should:
- Maintain on-hand at least a 30-day supply—and ideally a 90-day supply—of antiretroviral (ARV) drugs and other medications.
- Talk to their pharmacists and/or healthcare providers about changing to mail order delivery of medications when possible.
- Persons for whom a regimen switch is planned should consider delaying the switch until close follow-up and monitoring are possible.
- Lopinavir/ritonavir (LPV/r) has been used as an off-label treatment for patients with COVID-19 and clinical trials are underway globally. If protease inhibitors (PIs) are not already part of a person’s ARV regimen, their regimen should not be changed to include a PI to prevent or treat COVID-19, except in the context of a clinical trial and in consultation with an HIV specialist. In a small open-label trial, 199 hospitalized patients with COVID-19 were randomized to either 14 days of LPV/r plus standard of care or standard of care alone. No statistically significant difference was seen between the two groups, with regards to time to clinical improvement or mortality.1
Note: During the COVID-19 Response, 90-day prescriptions are available for all uninsured clients utilizing ADAP formulary and for all insured clients based on their BCBS insurance plans allowable until June 30, 2020.
Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020. Available at: https://www.ncbi.nlm.nih.gov/pubmed/32187464.
"KML" App Now Available
KML AL is an app that seeks to encourage individuals to "Know Your Status, Manage Your Health, and Live Your Best Life." It is an information source that seeks to help prevent the transmission of HIV and to help those with HIV in managing their disease. The app gives information on how HIV is transmitted, how to prevent HIV, how to get tested for HIV, and how to manage the disease. It's available now from iTunes and Google Play.
ADAP and Part B Services Annual Report
The ADAP and Part B Services Annual Report 2018 is now available. This report reflects the clients actively enrolled in ADAP as of December 31, 2018, and clients receiving Part B core medical and support services during 2018. ADAP and Part B services clients achieve optimal health outcomes at a higher rate than all persons living with HIV in Alabama, with the majority of ADAP and Part B services clients already surpassing or approaching the National HIV/AIDS Strategy (NHAS) 2020 indicators of 90 percent retention in HIV medical care and 80 percent viral suppression.
The Start Talking Alabama campaign seeks to increase HIV awareness and decrease the stigma by sharing prevention, testing, and treatment information, and support.
Every Dose Every Day App
The CDC's new Every Dose Every Day app is designed to help providers support medication adherence among people living with HIV. Medication adherence improves health outcomes and increases the prevention benefits of treatment. Visit the CDC to learn more about the app.
Molecular HIV Surveillance in Alabama, 2010-2015
This report is now available online.
Brief Facts on African-Americans and HIV in Alabama
This report is now available online.
Continuum of HIV Care by Public Health Area
The Finalized 2017 HIV Continuum of Care depicts persons living with HIV (PWH) in Alabama who are engaged in selected stages of HIV treatment. Successful HIV Prevention and Care programs exhibit high linkage to care among newly diagnosed clients, as well as effective retention in care and adequate viral load suppression among existing HIV-positive clients. As viral load is considered a measure of infectivity, maintaining a suppressed viral load decreases the likelihood of infecting another person and is the focus of Treatment as Prevention strategies. PWH who adhere to antiretroviral treatment and maintain suppressed viral loads can reduce the risk of sexual transmission of HIV by 96 percent. For PWH who reach undetectable levels, there are no documented cases of sexual transmission. This is the premise of the Prevention Access Campaign's Undetectable Equals Unstransmittable (U=U) initiative, which the Centers for Disease Control and Prevention supports, agreeing there is "effectively no risk" of sexually transmitting HIV when on treatment and undetectable.
The Preliminary 2018 HIV Continuum of Care is also available. Note that 2018 data should be interpreted with extreme caution as not all reported cases have been investigated and entered into the HIV Surveillance database. 2018 data will be finalized December 31, 2019, allowing a full twelve months for reporting delays.
HIV and Pregnancy
The Office of HIV Prevention and Control collaborates with Alabama's medical providers to reduce the incidence of perinatal HIV infection. Visit HIV and Pregnancy for more information.
STD/HIV REPORT Card
Physicians, dentists, nurses, medical examiners, hospital administrators, nursing home administrators, lab directors, school principals, and day care directors are responsible for reporting Notifiable Diseases in Alabama. The Alabama Notifiable Diseases Rules, Chapter 420-4-1, specifies the diseases and conditions requiring notification, and the time frame and methods for notification. To report a case of HIV (including symptomatic infection, AIDS, CD4 counts and viral load), please use the Communicable Disease REPORT Card.
This site contains HIV prevention messages that may not be appropriate for all audiences. Since HIV infection is spread primarily through sexual practices or by sharing needles, prevention messages and programs may address these topics. If you are not seeking such information or may be offended by such materials, please exit this website.
Page last updated: March 23, 2020